# Comparison of the Effectiveness and Tolerability of Exenatide Once-weekly Compared to Basal Insulins

> **NCT02974244** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 7000 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** exenatide once weekly
- **DRUG:** basal insulin

## Key facts

- **NCT ID:** NCT02974244
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10-28
- **Primary completion:** 2014-10-28
- **Final completion:** 2014-10-28
- **Target enrollment:** 7000 (ACTUAL)
- **Last updated:** 2017-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02974244

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02974244, "Comparison of the Effectiveness and Tolerability of Exenatide Once-weekly Compared to Basal Insulins". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02974244. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*